Legis Daily

Strengthening Average Sales Price Reporting Act of 2019

USA116th CongressS-2051| Senate 
| Updated: 6/28/2019
Robert Menendez

Robert Menendez

Democratic Senator

New Jersey

Cosponsors (1)
Todd Young (Republican)

Finance Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Strengthening Average Sales Price Reporting Act of 2019 This bill requires certain manufacturers of drugs that are covered under Medicare medical services to report pricing information to the Centers for Medicare & Medicaid Services. Specifically, manufacturers of such drugs that do not have rebate agreements under the Medicaid Drug Rebate Program must report similar information as is required under the program, including average sales price, total units, and wholesale acquisition cost. Manufacturers that fail to comply or that report false information are subject to civil penalties.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Jun 28, 2019
Introduced in Senate
Jun 28, 2019
Read twice and referred to the Committee on Finance.
  • June 28, 2019
    Introduced in Senate


  • June 28, 2019
    Read twice and referred to the Committee on Finance.

Health

Related Bills

  • HR 116-1570: Removing Barriers to Colorectal Cancer Screening Act of 2020
  • HR 116-2296: More Efficient Tools to Realize Information for Consumers Act
  • S 116-3129: Lower Costs, More Cures Act of 2019
  • HR 116-2113: Prescription Drug STAR Act
  • HR 116-2087: Drug Price Transparency Act
  • HR 116-19: Lower Costs, More Cures Act of 2019
Administrative law and regulatory proceduresCivil actions and liabilityCongressional oversightConsumer affairsHealth care costs and insuranceHealth information and medical recordsInsurance industry and regulationMedicarePrescription drugsRetail and wholesale trades

Strengthening Average Sales Price Reporting Act of 2019

USA116th CongressS-2051| Senate 
| Updated: 6/28/2019
Strengthening Average Sales Price Reporting Act of 2019 This bill requires certain manufacturers of drugs that are covered under Medicare medical services to report pricing information to the Centers for Medicare & Medicaid Services. Specifically, manufacturers of such drugs that do not have rebate agreements under the Medicaid Drug Rebate Program must report similar information as is required under the program, including average sales price, total units, and wholesale acquisition cost. Manufacturers that fail to comply or that report false information are subject to civil penalties.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Jun 28, 2019
Introduced in Senate
Jun 28, 2019
Read twice and referred to the Committee on Finance.
  • June 28, 2019
    Introduced in Senate


  • June 28, 2019
    Read twice and referred to the Committee on Finance.
Robert Menendez

Robert Menendez

Democratic Senator

New Jersey

Cosponsors (1)
Todd Young (Republican)

Finance Committee

Health

Related Bills

  • HR 116-1570: Removing Barriers to Colorectal Cancer Screening Act of 2020
  • HR 116-2296: More Efficient Tools to Realize Information for Consumers Act
  • S 116-3129: Lower Costs, More Cures Act of 2019
  • HR 116-2113: Prescription Drug STAR Act
  • HR 116-2087: Drug Price Transparency Act
  • HR 116-19: Lower Costs, More Cures Act of 2019
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Administrative law and regulatory proceduresCivil actions and liabilityCongressional oversightConsumer affairsHealth care costs and insuranceHealth information and medical recordsInsurance industry and regulationMedicarePrescription drugsRetail and wholesale trades